Feedback / Questions
Elayta (CT1812) - Cognition Therap
https://www.globenewswire.com/news-release/2023/02/09/2604967/0/en/Cognition-Therapeutics-Completes-Enrollment-of-CT1812-Phase-2-SEQUEL-Study-for-Mild-to-Moderate-Alzheimer-s-Disease.html
Feb 9, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next